USNA

In the past six months (approximately April to October 2026), USANA Health Sciences' stock experienced significant volatility and a downward trend, decreasing by 20.07% over six months and 44.3% over the past year. A major event was the Q2 CY2026 earnings report around August 5, 2026, where USANA reported a loss of $0.07 per share, missing analyst expectations of a $0.43 profit, and revenue of $223 million, falling short of the $235 million forecast. This led to a sharp stock decline of 34.2% on August 5, 2026, plunging to $16.29. The earnings miss was attributed to a $29 million non-cash goodwill impairment charge on the Hiya unit, issues with Rise Wellness packaging, and higher digital advertising costs. Management subsequently lowered its full-year 2026 adjusted EPS and overall revenue guidance, citing a challenging digital marketing environment for Hiya and reduced near-term sales for Rise Wellness, alongside a continued shrinking of the core direct selling business and a decline in active customers.